Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

202418 citationsJournal Articlehybrid Open Access

Authors

ClinicalTrials.gov Identifier: NCT01953588.

Good health and well-being

Published in: JAMA Oncology

Volume 10, Issue 3, pp. 362-362

Field-Weighted Citation Impact: 5.09